

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

For the month of June 2017

Commission File Number: 001-37643

**KITOV PHARMACEUTICALS HOLDINGS LTD.**  
(Translation of registrant's name into English)

**One Azrieli Center, Round Tower, 23<sup>rd</sup> Floor, Tel Aviv 6701101, Israel**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_

---

---

Further to our Notice of the Special General Meeting of our Shareholders to be held on Wednesday, July 12, 2017 at 4:30 PM Israel time, at the offices of Kitov Pharmaceuticals Holdings Ltd. (hereinafter, the "Registrant" or the "Company") at One Azrieli Center, Round Tower, 23<sup>rd</sup> Floor, 132 Menachem Begin Road, Tel Aviv, Israel (the "Meeting"), and the Proxy Statement for the Meeting, which we previously published on our website and also furnished to the SEC on Form 6-K, as well as submitted to the Israeli Securities Authority and Tel Aviv Stock Exchange, and made available on their respective websites for listed company reports: [www.magna.isa.gov.il](http://www.magna.isa.gov.il) and [www.maya.tase.co.il](http://www.maya.tase.co.il), we are also publishing a form of the Voting Instruction Form for holders of our American Depositary Shares ("ADSs") which will be distributed to holders of our ADSs by BNY Mellon, the Depository of our ADS program. A copy of the Voting Instruction Form will also be submitted to the Israeli Securities Authority and Tel Aviv Stock Exchange, and available on their respective websites for listed company reports: [www.magna.isa.gov.il](http://www.magna.isa.gov.il) and [www.maya.tase.co.il](http://www.maya.tase.co.il), and will also be made available on our corporate website at <http://kitovpharma.investorroom.com/Shareholder-Meetings>.

ADS holders should return their BNY Mellon Voting Instruction Form for holders of our ADSs by no later than the date and time set forth on such Voting Instruction Form, namely by no later than 12:00 P.M.EST on July 6, 2017. Under the terms of the Depositary Agreement among the Company, BNY Mellon (which acts as the Depository) and the holders of our ADSs, upon the written request of an owner of ADSs, as of the date of the request or, if a record date was specified by the Depository, as of that record date, received by the Depository on or before any instruction cutoff date established by the Depository in its notices to ADS holders, the Depository shall, endeavor, in so far as practicable, to vote or cause to be voted the number of deposited ordinary shares represented by those ADSs in accordance with the instructions set forth in that request. We have instructed the Depository to disseminate a notice of the Meeting, and have given the Depository notice of the Meeting, details concerning the matters to be voted upon and copies of materials to be made available to holders of ordinary shares in connection with the Meeting not less than 30 days prior to the Meeting date. The Depository shall not vote or attempt to exercise the right to vote that attaches to the deposited ordinary shares other than (a) in accordance with instructions given by owners and received by the Depository; or, (b) as provided in the following sentences. If no instructions are received by the Depository from an owner of ADSs with respect to a matter and a number of ADSs of that owner on or before the instruction cutoff date set forth on the BNY Mellon Voting Instruction Form, the Depository shall deem that owner to have instructed the Depository to give a discretionary proxy to a person designated by us with respect to that matter and the number of ordinary shares of the Company represented by that number of ADSs, and the Depository shall give a discretionary proxy to a person designated by us to vote that number of ordinary shares of the Company as to that matter, except that no instruction of that kind shall be deemed given and no discretionary proxy shall be given with respect to any matter as to which we inform the Depository (and we agree to provide such information as promptly as practicable in writing, if applicable) that (x) we do not wish a proxy given, (y) substantial shareholder opposition exists, or (z) the matter materially and adversely affects the rights of holders of shares.

Information contained on, or that can be accessed through, our website does not constitute a part of this Form 6-K, nor does it form part of the proxy solicitation materials in connection with the Meeting. We have included our website address in this Form 6-K solely as an inactive textual reference. We will post on our website any materials in connection with the Meeting required to be posted on such website under applicable corporate or securities laws and regulations.

This report on Form 6-K of the Registrant consists of the following document, which is attached hereto and incorporated by reference herein:

Exhibits

99.1 [Voting Instruction Form for holders of American Depositary Shares](#)

Forward-Looking Statements and the Company's Safe Harbor Statement

*Certain statements in this Report on Form 6-K are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully acquire, develop or commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the lack of sufficient funding to finance the clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents attained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent interference or infringement action; our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions; the uncertainty surrounding an investigation by the Israel Securities Authority into our historical public disclosures and the potential impact of such investigation on the trading of our securities or on our clinical, commercial and other business relationships, or on receiving the regulatory approvals necessary in order to commercialize our products, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 and in our other filings with the SEC, including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement, or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, <http://www.sec.gov>.*

This Form 6-K is incorporated by reference into each of the Registrant's Registration Statements on Form F-3 filed with the Securities and Exchange Commission on December 12, 2016 (Registration file numbers 333-207117, 333-211477 and 333-215037), the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), and the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

June 12, 2017

**KITOV PHARMACEUTICALS HOLDINGS LTD.**

By: /s/ Avraham Ben-Tzvi  
Avraham Ben-Tzvi  
Company Secretary

---

**Special General Meeting of Shareholders of Kitov Pharmaceuticals Holdings Ltd.**

Date: July 12, 2017  
See Voting Instruction On Reverse Side.

Please make your marks like this:  Use pen only

1.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>	3C.ii.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>
2.	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	3C.iii.a	Yes <input type="checkbox"/> No <input type="checkbox"/>
2A.	Yes <input type="checkbox"/> No <input type="checkbox"/>	4.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>
3A.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>	4A.	Yes <input type="checkbox"/> No <input type="checkbox"/>
3A.i.	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	5.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>
3A.i.a	Yes <input type="checkbox"/> No <input type="checkbox"/>	5A.	Yes <input type="checkbox"/> No <input type="checkbox"/>
3A.ii.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>	6.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>
3A.ii.a	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	6A.	Yes <input type="checkbox"/> No <input type="checkbox"/>
3A.ii.ii.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>	7.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>
3A.ii.ii.a	Yes <input type="checkbox"/> No <input type="checkbox"/>	7A.	Yes <input type="checkbox"/> No <input type="checkbox"/>
3B.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>	8.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>
3B.i.	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	8.i.	Yes <input type="checkbox"/> No <input type="checkbox"/>
3B.i.a	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>	8.i.a	Yes <input type="checkbox"/> No <input type="checkbox"/>
3B.ii.	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	8.ii.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>
3B.ii.a	Yes <input type="checkbox"/> No <input type="checkbox"/>	8.ii.a	Yes <input type="checkbox"/> No <input type="checkbox"/>
3B.ii.ii.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>	8.ii.ii.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>
3B.ii.ii.a	Yes <input type="checkbox"/> No <input type="checkbox"/>	8.ii.ii.a	Yes <input type="checkbox"/> No <input type="checkbox"/>
3C.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>	8.ii.ii.a	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>
3C.i.	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	8.ii.ii.a	Yes <input type="checkbox"/> No <input type="checkbox"/>
3C.i.a	Yes <input type="checkbox"/> No <input type="checkbox"/>	8.ii.ii.a	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>
3C.ii.	For <input type="checkbox"/> Against <input type="checkbox"/> Abstain <input type="checkbox"/>	8.v.	Yes <input type="checkbox"/> No <input type="checkbox"/>
3C.ii.a	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	8.v.a	Yes <input type="checkbox"/> No <input type="checkbox"/>

If marked "YES" to any matter requiring a declaration of a "personal interest", please provide details as indicated below: Following are details of my personal interest, as such term is defined in Section 1 of the Companies Law, in the matter(s) of the Proposal(s) for which I marked "YES" as having a personal interest.

**Authorized Signatures - This section must be completed for your instructions to be executed.**

_____	_____
Please Sign Here	Please Date Above
_____	_____
Please Sign Here	Please Date Above

**Special General Meeting of Shareholders of Kitov Pharmaceuticals Holdings Ltd. to be held on July 12, 2017 For Holders as of June 6, 2017**



- Mark, sign and date your Voting Instruction Form.
- Detach your Voting Instruction Form.
- Return your Voting Instruction Form in the postage-paid envelope provided.

All votes must be received by 12:00 p.m. EST on July 6, 2017.

To review AGM related materials, including the full Proxy Statement, please visit: <http://kitovpharma.investorroom.com/ShareholderMeetings>

PROXY TABULATOR FOR  
KITOV PHARMACEUTICALS HOLDINGS LTD.  
P.O. BOX 8016  
CARY, NC 27512-9903

↑ Please separate carefully at the perforation and return just this portion in the envelope provided. ↑



EVENT #

CLIENT #

**KITOV PHARMACEUTICALS HOLDINGS LTD.**  
**Instructions to The Bank of New York Mellon, as Depositary**  
**(Must be received prior to 12:00 p.m. EST on July 6, 2017)**

The undersigned registered owner of American Depositary Shares hereby requests and instructs The Bank of New York Mellon, as Depositary, to endeavor, in so far as practicable, to vote or cause to be voted the amount of Shares or other Deposited Securities represented by such Shares of Kitov Pharmaceutical Holdings Ltd. Registered in the name of the undersigned on the books of the Depositary as of the close of business on June 6, 2017 at the Special General Meeting of the Shareholders of Kitov Pharmaceutical Holdings Ltd. to be held on July 12, 2017 or any postponement or adjournment thereof in respect of the resolutions specified on the reverse.

**NOTES:**

1. Please direct the Depositary how it is to vote by placing an "X" in the appropriate box opposite each agenda item. It is understood that, if this form is signed and returned but no instructions are indicated in the boxes, then a discretionary proxy will be given to a person designated by the Company.
2. It is understood that, if this form is not signed and returned, the Depositary will deem such holder to have instructed the Depositary to give a discretionary proxy to a person designated by the Company.  
 (Continued and to be marked, dated and signed, on the other side)

- |  |  |
|--|--|
| <p>1. To approve an increase in the number of ordinary shares reserved under Kitov Pharmaceuticals Holdings Ltd. 2016 Equity-Based Incentive Plan to 50,000,000 ordinary shares to qualify for incentive stock options for US tax purposes.</p> <p>2. To approve the Compensation Policy, in the form attached as Exhibit A to the Company's Proxy Statement.</p> <p>2A. Do you have a Personal Interest in the Matter of Proposal no. 2? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 2)</p> <p>3A. To approve the Letter of Exemption granted by the Company to the director so named, which is in the form of such letter previously approved by the shareholders to be granted by the Company to directors serving from time to time in such capacity, a form of which is attached as Exhibit 10.5 to the Registration Statement on Form F-1 of the Company filed with the SEC on September 24, 2015.</p> <p>3A.i. Mr. Arye Weber<br/>         3A.i.a. Do you have a Personal Interest in the Matter of Proposal no. 3A.i? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 3A.i.)</p> <p>3A.ii. Ms. Ravit Sten-Ruff<br/>         3A.ii.a. Do you have a Personal Interest in the Matter of Proposal no. 3A.ii? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 3A.ii.)</p> <p>3A.iii. Mr. Ran Tzor<br/>         3A.iii.a. Do you have a Personal Interest in the Matter of Proposal no. 3A.iii? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 3A.iii.)</p> <p>3B. To approve Letter of Indemnity granted by the Company to the director so named, which is in the form of such letter previously approved by the shareholders to be granted by the Company to directors serving from time to time in such capacity, a form of which is attached as Exhibit 10.6 to the Registration Statement on Form F-1 of the Company filed with the SEC on September 24, 2015.</p> <p>3B.i. Mr. Arye Weber<br/>         3B.i.a. Do you have a Personal Interest in the Matter of Proposal no. 3B.i? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 3B.i.)</p> <p>3B.ii. Ms. Ravit Sten-Ruff<br/>         3B.ii.a. Do you have a Personal Interest in the Matter of Proposal no. 3B.ii? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 3B.ii.)</p> <p>3B.iii. Mr. Ran Tzor<br/>         3B.iii.a. Do you have a Personal Interest in the Matter of Proposal no. 3B.iii? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 3B.iii.)</p> <p>3C. To approve the inclusion under the D&amp;O Policy of the Company of the director so named, effective as of the commencement of such director's engagement with the Company.</p> <p>3C.i. Mr. Arye Weber<br/>         3C.i.a. Do you have a Personal Interest in the Matter of Proposal no. 3C.i? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 3C.i.)</p> <p>3C.ii. Ms. Ravit Sten-Ruff<br/>         3C.ii.a. Do you have a Personal Interest in the Matter of Proposal no. 3C.ii? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 3C.ii.)</p> | <p>3C.iii. Mr. Ran Tzor<br/>         3C.iii.a. Do you have a Personal Interest in the Matter of Proposal no. 3C.iii? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 3C.iii.)</p> <p>4. To approve that the Company may procure a D&amp;O Insurance Policy, as well as procure in the future additional D&amp;O Insurance Policies, and to include all current as well as future office holders under the coverage of any such D&amp;O Insurance Policies, effective as of the commencement of their engagement with the Company, as set forth under Proposal 4 of the Proxy Statement.</p> <p>4A. Do you have a Personal Interest in the Matter of Proposal no. 4? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 4)</p> <p>5. To approve an amendment to the terms of office and employment of Dr. John Paul Waymack, the Chairman of the Board of Directors and Chief Medical Officer of the Company, including the grant of equity-based incentive compensation, as set forth under Proposal 5 in the Proxy Statement.</p> <p>5A. Do you have a Personal Interest in the Matter of Proposal no. 5? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 5)</p> <p>6. To approve an amendment to the terms of office and employment of Mr. Isaac Israel a member of the Board of Directors and Chief Executive Officer of the Company, including the grant of equity-based incentive compensation, as set forth under Proposal 6 in the Proxy Statement.</p> <p>6A. Do you have a Personal Interest in the Matter of Proposal no. 6? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 6)</p> <p>7. To approve an amendment to the terms of office and employment of Mr. Simcha Rosh a member of the Board of Directors and Chief Financial Officer of the Company, including the grant of equity-based incentive compensation, as set forth under Proposal 7 in the Proxy Statement.</p> <p>7A. Do you have a Personal Interest in the Matter of Proposal no. 7? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 7)</p> <p>8. To approve an amendment to the terms of office and employment of the director so named, including the grant of equity-based incentive compensation, as set forth under Proposal 8 in the Proxy Statement.</p> <p>8.i. Mr. Arye Weber<br/>         8.i.a. Do you have a Personal Interest in the Matter of Proposal no. 8.i? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 8.i.)</p> <p>8.ii. Ms. Ravit Sten-Ruff<br/>         8.ii.a. Do you have a Personal Interest in the Matter of Proposal no. 8.ii? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 8.ii.)</p> <p>8.iii. Mr. Ran Tzor<br/>         8.iii.a. Do you have a Personal Interest in the Matter of Proposal no. 8.iii? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 8.iii.)</p> <p>8.iv. Mr. Ho Agnon<br/>         8.iv.a. Do you have a Personal Interest in the Matter of Proposal no. 8.iv? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 8.iv.)</p> <p>8.v. Mr. Steven Steinberg<br/>         8.v.a. Do you have a Personal Interest in the Matter of Proposal no. 8.v? (MUST BE COMPLETED FOR VOTE TO BE COUNTED ON PROPOSAL 8.v.)</p> |
|--|--|

PROXY TABULATOR FOR  
 KITOV PHARMACEUTICALS HOLDINGS LTD.  
 P.O. BOX 8016  
 CARY, NC 27512-9908